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Despite the plethora of immune modulating agents available in cancer treatment, their 
effectiveness relies on a functional immune system. However, the adverse side effects by 
chemotherapy impede the therapeutic benefits from immunotherapy. It remains a major 
challenge to prevent relapse for cancer patients who have already undergone rigorous 
chemotherapy. Lunasin, a 43-amino acid peptide, was originally isolated from soybeans. Our 
team has recently discovered a novel function of lunasin as an immune modulating agent that 
exerts robust synergistic effects imposed by several therapeutic cytokines. Such synergism 
strongly augments IFNγ and granzyme B expression by Natural Killer (NK) cells, which is 
associated with increased tumoricidal activity. The combination regimen with lunasin and 
cytokine is capable of restoring NK activation from lymphoma patients with chemotherapy-
induced immune dysfunction. Our results support the potential application of lunasin to improve 
the therapeutic effects of existing cytokine treatment that has been used to eliminate residual 
tumors cells from lymphoma patients after chemotherapy. We designate lunakine as new 
formulation by combing lunasin and selected cytokine (filed for US Patent Cooperation Treat). In 
working with Indiana University and Technology Corporation (IURTC), we have started a startup 
company, Immune Peptide Therapeutics (IPT), LLC. Our mission is to develop a more 
efficacious immunotherapy that prevents relapse and confers progression-free survival for 
cancer patients. With the support from FORCES, our team has successfully developed a 
second generation of lunasin called IPT.103 that deviates from its parental type. Activity of 
IPT.103 has been tested in vitro with EC50 of 0.78 µM as compared to 4.54 µM for lunasin, 
indicating an improved potency to induce IFNγ production by NK cells. The newly developed 
peptide IPT.103 is expected to strengthen the intellectual property (IP) position for 
commercialization. We are currently working on tumor models for preclinical assessment of 
IPT’s regimens in immunotherapy for lymphoma. 
